Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses by Lin, Yu & He, Yongqun
RESEARCH Open Access
Ontology representation and analysis of vaccine
formulation and administration and their effects
on vaccine immune responses
Yu Lin and Yongqun He*
* Correspondence: yongqunh@
umich.edu
Unit of Laboratory Animal Medicine,
Department of Microbiology and
Immunology, Center for
Computational Medicine and
Bioinformatics, University of
Michigan Medical School, Ann
Arbor, MI 48109, USA
Abstract
Background: A vaccine is a processed material that if administered, is able to
stimulate an adaptive immune response to prevent or ameliorate a disease. A
vaccination process may protect the host against subsequent exposure to an
infectious agent and result in reduced disease or total prevention of the disease.
Vaccine formulation and administration methods may affect vaccine safety and
efficacy significantly.
Results: In this report, the detailed classification and definitions of vaccine
components and vaccine administration processes are represented using OWL within
the framework of the Vaccine Ontology (VO). Different use cases demonstrate how
different vaccine formulations and routes of vaccine administration affect the
protection efficacy, general immune responses, and adverse events following
vaccination. For example, vaccinations of mice with Brucella abortus vaccine strain
RB51 using intraperitoneal or intranasal administration resulted in different protection
levels. As shown in the vaccine adverse event data provided by US FDA, live
attenuated and nonliving vaccines are usually administered in different routes and
have different local and systematic adverse effect manifestations.
Conclusions: Vaccine formulation and administration route can independently or
collaboratively affect host response outcomes (positive protective immunity or
adverse events) after vaccination. Ontological representation of different vaccine and
vaccination factors in these two areas allows better understanding and analysis of
the causal effects between different factors and immune responses.
Background
A vaccine is any processed material with the function that when administered, it can
prevent or ameliorate a disease or disorder in a target organism by inducing or modify-
ing adaptive immune responses specific to the antigens in the vaccine. After the stimu-
lation of a lasting immune response to a protective antigen(s), the host is able to resist
the infection of an infectious agent. Vaccine antigens include, for example, suspensions
of killed or attenuated microorganisms, or products or derivatives of microorganisms.
The most common method of administering vaccines is by injection, but some are
given by mouth or nasal spray.
The domain of the vaccine and vaccination research spans multiple areas: the patho-
gen, vaccine preparation, vaccine administration, vaccine-induced immune response,
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vaccine safety and efficacy. The Vaccine Ontology (VO) is a community-based ontology
in the field of vaccine and vaccination [1]. VO has been developed under the framework
of Basic Formal Ontology (BFO 1.1) [2], and it uses the Relation Ontology (RO) [3] to
represent commonly used relations. VO formally represents various vaccines including
those that are licensed, in clinical trial, or just proven effective in laboratory research. In
addition, VO ontologically represents different vaccine components and how different
components exist in any specific vaccine. VO also captures the knowledge of vaccin-
ation, immunization and the vaccine-host interactions. Figure 1 represents selected top
level core VO terms relevant to this study; it includes vaccine, vaccine component, route
of administration, vaccination, immunization, and vaccine-induced host response. Be-
cause of their importance, vaccine-induced immune responses and vaccine protection
against targeted diseases or pathogens are emphasized in VO. In addition to vaccine-
specific terms, VO has also included terms imported from more than 10 existing ontolo-
gies, such as the Chemical Entities of Biological Interest (CHEBI) [4], the Ontology for
Biomedical Investigations (OBI) [5], and the Infectious Disease Ontology (IDO) [6].
These reliable biomedical ontologies provide higher level terms or important entities
that are used in VO, and reusing them supports ontology interoperability.
Vaccine-induced host responses can be protective immunity (desired response) or ad-
verse events (undesired responses). The induction of protective immunity is the out-
come of vaccine efficacy. The appearance of adverse events is often due to the side
effects of a vaccine and is an important topic of vaccine safety. To study the efficacy
and safety of a vaccine, the knowledge of vaccine formulation and administration is
very important. We hypothesize that the differences in vaccine formulation and
Figure 1 Selected core VO terms relevant to the presented research. This figure shows a list of VO
core terms relevant to the targeted study. VO is developed under the BFO framework. The VO term ‘vaccine
component’ is a BFO ‘material entity’. A ‘vaccine’ is an OBI ‘processed material entity’. A ‘route of
administration’ is a subclass of ‘BFO: site’. ‘vaccine-induced host response’, ‘vaccine-induced adaptive
immune response’, ‘immunization’, ‘vaccine immunization’ and ‘vaccination’ are all processes, i.e., ‘processual
entity’ in BFO. Note that ‘vaccination’ is asserted as ‘administering substance in vivo’ from OBI. Vaccination is
the process of administering a vaccine into a host. It differs from vaccine immunization that is a biological
process that starts at vaccination and results in an outcome of the host getting immunized.
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administration will change the induction of vaccine-induced protective immunity and
adverse events. This hypothesis has not been systematically addressed at the ontological
level. In this report, we first represent various vaccine formulations and routes of vac-
cine administration in VO, and then discuss how different vaccine formulations and
vaccination routes influence the outcomes of vaccination, including protective immune
responses and adverse events.
Results
In what follows, italics are used to refer to ontology relation terms, logical or textual
definitions of ontology terms. Single quotation marks ‘ ’ are used to cite other class and
instance level ontology terms.
Representing vaccine components in VO
The final form of a vaccine is often a mixture of different ingredients. In the manufac-
turing of licensed vaccine products, the vaccine formulation refers to a uniform mix-
ture of all vaccine components into a single vessel. A vaccine is a mixture of different
components including vaccine antigen, adjuvant, and buffer. In VO, a ‘vaccine compo-
nent’ is defined as a material entity that is part of a vaccine. The logical definition of
‘vaccine component’ in VO is: ‘material entity’ and (part_of some ‘vaccine’). Different
Figure 2 Vaccine component represented in VO.
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ingredients of vaccines were classified into subclasses under the class ‘vaccine compo-
nent’ (Figure 2). Selected vaccine components related to this study are described below:
‘Pathogen organism vaccine component’: a vaccine component that is either a
pathogen organism or derived from a pathogen organism. This term is logically defined
in VO as: 'vaccine component' and (organism or ('is part of' some organism)).
The pathogen organism used for vaccine development is an output of the vaccine
preparation process, which includes propagation of the pathogen in a culture medium,
followed by isolation and purification of the organism. Live attenuated or killed
virulent pathogens can be used as a key component of a vaccine. A killed or
inactivated vaccine is produced by killing the pathogenic microbe with chemicals, heat
or radiation. A live attenuated vaccine contains living microbe that has been weakened
(attenuated) in a laboratory setting so it can no longer cause severe disease. A vaccine
that has live attenuated pathogen as a component is defined as a ‘live attenuated
vaccine’ in VO. Similarly, a vaccine that has killed or inactivated pathogen as a
component is defined as a ‘killed or inactivated vaccine’. Vaccines use proteins,
peptides, lipopolysaccharides, or polysaccharides of a pathogen as their components
defined as ‘subunit vaccine’ in VO. Vaccines use the DNA or RNA sequence of a
pathogen organism as component is a DNA or RNA vaccine.
‘Vaccine antigen’: An immunogenic antigen in a vaccine. A vaccine antigen is
typically a modified or partial form of a virus, bacterium, or toxin that causes a
disease. VO’s logical definition is: ‘vaccine component’ and has role some ‘antigen role’.
The vaccine antigen is able to induce an immune response. An example of a vaccine
antigen is a protein from a pathogen organism as described above. Note that some
subclasses of ‘pathogen organism vaccine component’ bears ‘vaccine antigen role’ such
as some proteins, peptides, lipopolysaccharides and polysaccharides used for vaccine
component. However, some other ‘pathogen organism vaccine component’ may not
bear the ‘vaccine antigen role’. For example, the host may not produce any immune
response to some component (e.g., water, some metabolites, and some peptides) of a
pathogen organism.
‘Vaccine conjugate protein’: is a protein that is chemically conjugated to a vaccine
antigen and is used to enhance vaccine-induced immune response. A vaccine that uses
a conjugate protein called a conjugate vaccine. The conjugate protein may help to
induce the T-cell-dependent immune response and confer immune memory to a
vaccine antigen. The logical definition for ‘vaccine conjugate protein’ in VO is: 'vaccine
component' and (bearer_of some 'vaccine conjugate role').
‘Vaccine additive’: is a material added to the antigenic component by the vaccine
manufacturer for a specific purpose, such as stabilizing the final product as in vaccine
stabilizer, strengthening vaccine induced immune response as in vaccine adjuvant, and
preventing serious adverse effect such as Staphylococcus infection as in vaccine
presevatives. The term is logically defined in VO as: 'vaccine component' and
(bearer_of some 'vaccine additive role'). Vaccine additives include adjuvants,
preservatives and stabilizers, as well as materials that are added to affect pH and
isotonicity [7].
An important vaccine additive is ‘vaccine adjuvant’: a vaccine additive incorporated
into a vaccine to enhance the immunogenicity of vaccine antigens. Adjuvants can
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function as immunostimulants, vehicles, and carriers. In general, the adjuvant effect
can be divided into two principal components: (1) antigen depot and delivery and (2)
immune potentiation by targeting antigens to antigen presenting cells (APC) [8,9].
Vaccine delivery systems are generally particulates, e.g., emulsions, microparticles,
immune stimulating complexes (ISCOMS) and liposomes. The particulate
characteristics facilitate uptake by APCs and transport to secondary lymph organs,
resulting in the induction of immune responses [9]. The logical definition of this term
in VO is: 'vaccine additive' and ('has role' some 'vaccine adjuvant role').
‘Vaccine vector’: a vector that is used in a genetically engineered vaccine to transport
and express genes coding for antigens into the body to induce an immune response.
Examples of a vaccine vector include a plasmid vector for the generation of a DNA
vaccine and a weakened or killed version of a virus or bacterium that cannot cause a
disease in hosts (e.g., human). VO logically define vaccine vector as 'vaccine
component' and (bearer_of some 'vaccine vector role').
Different vaccine components may share similar functions. For example, vaccine ad-
juvant and vaccine conjugate protein both help to induce stronger immune responses.
A vaccine conjugate protein is chemically bound to a vaccine antigen, whereas, a vac-
cine adjuvant is just mixed with the vaccine without any chemical conjugation. A vac-
cine conjugate protein may by itself induce host immune response, but a vaccine
adjuvant usually does not. Another example is vaccine vector and vaccine adjuvant,
both of which convey a carrier’s function. A vaccine vector carries the genetic material
that encodes for a protein antigen. However, a vaccine adjuvant delivery system carries
the vaccine antigen per se. These important differentiations are captured using defin-
ition of roles. For example, the definition of ‘vaccine vector role’ in VO is “a biological
vector role that is realized by the process of transmitting genetic material encoding vac-
cine antigen to a vaccinee, when introduced into the vaccinee, it results in the in situ
production of antigen in the vaccinee” [10].
Several roles including ‘vaccine additive role’, ‘vaccine adjuvant role’, ‘vaccine stabilizer
role’, ‘vaccine preservative role’, ‘vaccine vector role’ and ‘vaccine conjugate role’ are gen-
erated in VO. Bearers of these roles are corresponding vaccine components. Through
the definition of roles, the usages and purposes of different vaccine components be-
come clearly defined in VO.
Vaccine administration
The route of a vaccine administrated into a vaccinee is another key factor for evaluating
a vaccine’s efficacy and safety. For example, if administered through nose, a vaccine
may induce stronger mucosal immune response but weaker systematic immunity than
that through injection. Based on He’s previous work of term ‘vaccination’ as a child
term of ‘administering substance in vivo’ [11], more detailed classification of subtypes
of vaccination were given in this paper.
There are two ways to differentiate different vaccination: 1) based on frequency; and
2) based on entry location. For the first categorization, there are ‘primary vaccination’,
and ‘boost vaccination’. ‘Boost vaccination’ has ‘secondary vaccination’, ‘tertiary vaccin-
ation’, and ‘quaternary vaccination’ as its children. The ontological relation between
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those vaccinations ‘is preceded by’ describes a temporal link between classes of pro-
cesses [3]. For example, in VO, the ‘boost vaccination’ is preceded by ‘primary vaccin-
ation’, which indicates that if a vaccinee has his/her boost vaccination, he/she must
have had a primary vaccination some time earlier.
Another classification of vaccinations is based on the entry locations of a vaccine ad-
ministration. Specifically, a vaccination can be classified as intramuscular (i.m.), intra-
peritoneal (i.p.), intragastric (i.g.), intradermal (i.d.), subcutaneous (s.c.), percutaneous,
intravenous (i.v.), intravesical, oral, intranasal (i.n.) vaccination and many others
(Figure 3A). The ontological definition for this subtype of vaccination utilizes the rela-
tion ‘unfolds_in’ and a ‘route of administration’. For example, an ‘intravenous vaccin-
ation’ is defined as ‘vaccination and unfolds in some intravenous route’. NCI thesaurus
(http://ncit.nci.nih.gov/) hosts the term ‘route of administration’ from Clinical Data
Interchange Standards Consortium (CDISC) terminology (http://www.cdisc.org). We
adopted and refactored this term in VO. The term ‘route of administration’ is asserted
as a subclass of BFO:site (Figure 3B). It means the fiat path where the vaccine is being
taken into body, which starts with the vaccine entry point of body and ends at the site
of action in the body. It is asserted with a description logical constrain: ‘is located in’
some ‘gross anatomical part’. Using this parent term, a subclass term oral route is logic-
ally defined as: ‘route of administration and is located in some (mouth or stomach)’.
During a vaccine administration process, the site of vaccination is often needed to be
recorded. Term ‘vaccination site’ and ‘vaccine injection site’ have been created for this
purpose. Both the terms refer to a site of the host body where a vaccine enters into
host. A ‘vaccine injection site’ explicitly refers to where injection needle or needles
pierced through, and a vaccination site may refer to a location of the body (e.g., nose or
skin) where a needle free delivery system delivers vaccine. The ‘vaccination site’ is mod-
eled as part of an administration route. Specifically, an administration route is the fiat
path of an administration, and the vaccination site is the entrance point of an adminis-
tration route. By this treatment, vaccination through oral route or intranasal route has
no vaccine injection site but has a vaccination site.
Figure 3 VO classification of (A) vaccination (B) route of administration.
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Effects of formulation and administration to vaccine-induced immune responses
The immune responses induced by a vaccine may be affected by many factors, includ-
ing the type of vaccine, vaccine dose, route of administration and the presence of an
adjuvant. Host factors such as age, nutritional factors, genetics, and coexisting disease
may also affect the response [12]. Here we show how different vaccine formulations
and routes of administration will affect the immune responses in the host after
vaccination.
Effects of formulation to vaccine-induced immune responses
Many examples can be used to demonstrate the important role of formulation to the
vaccine-induced immune responses. For instance, killed or live attenuated vaccines turn
to induce different immune responses. Live attenuated vaccines usually induce superior
protection against subsequent challenge [13]. However, they often present safety risks.
In contrast, vaccines based on killed whole pathogens, although safe, typically induce
weak cellular immunity [14]. One primary reason is that killed pathogen cannot infect
the host and replicate, a process that typically stimulates strong host response. Another
reason is that the physical or chemical treatments used for killing pathogens may result
in the denaturation of the antigen proteins or damage of the organism [15].
Brucella abortus strain RB51 is a live attenuated vaccine against cattle brucellosis
[16]. It has been licensed for commercial use in the US and many other countries. Live
RB51 can induce both cell-mediated and humoral immunity against virulent Brucella
infection. However, killed whole pathogen organism of RB51 fails to induce protective
cell-mediated immunity [17]. Another example is influenza vaccines. Currently there
are both trivalent live attenuated or inactivated influenza vaccines available in the
market. Although both live and inactivated influenza vaccines induce similar
humoral responses, only live attenuated vaccines induce diverse T-cell responses in
young children [18].
Killed vaccines typically induce Th2 immune response. One approach for improving
the performance of killed vaccine is to use an effective vaccine adjuvant. To avoid
strong adverse effects and still induce strong immune response, it is often feasible
to use gamma-irradiated pathogen that cannot replicate but remain metabolically
active for a period of time to induce antigen-specific immune response as live attenu-
ated vaccine [14,19].
The usage of conjugate vaccines is another example of the effect of formulation to
vaccine-induced immune response. Polysaccharide (PS) antigens of many pathogenic
bacteria induce only weak and short immune response, especially in young children
populations, due to their immunological naivety and a degree of immunoincompetence
condition [20]. The response to a capsular PS is T-cell-independent, meaning that B
lymphocytes proliferate and produce antibody without the help of T cells [21]. Conju-
gate vaccines are formed by linking capsular polysaccharides to a protein carrier, such
as tetanus toxoid, diphtheria toxoid, or Corynebacterium diphtheriae cross-reactive ma-
terial (CRM197). Conjugate vaccines may induce T-cell-dependent immunologic
responses that confer immune memory. In the USA, three meningococcal vaccines are
approved by FDA: conjugate vaccine MenactraW by Sanofi Pasteur, conjugate vaccine
MenveoW by Novartis Vaccines and Diagnostics, and polysaccharide vaccine
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Menomune -A/C/Y/W-135W (MPSV4) by Sanofi Pasteur. All these vaccines are using
meningococcal polysaccharide from serogroups A,C,W-135 and Y as vaccine antigens.
MenactraW and MenveoW, but not polysaccharide vaccine MenomuneW are able to in-
duce high immunogenicitiy and immunologic memory especially in young children
population [7].
Effect of vaccine administration route to protective immunity
The route of administration also plays a role in the efficacy of a vaccine. A vaccine pro-
tection investigation includes three processes: vaccination, pathogen challenge, and vac-
cine protection efficacy assessment. A measurement of vaccine efficacy is often
assessed by host survival for the pathogens (e.g., Influenza virus) which kill the infected
host (e.g., mouse) [22]. Many pathogens such as virulent Brucella [23] cannot kill
infected host. In this case, different methods have to be generated to measure the vac-
cine efficacy. For example, the measurement of Brucella colony forming units (CFU) in
spleens and/or livers of infected or noninfected mice measurement is established to
measure diminished replication in a vaccinated host than that in unvaccinated host
[23]. After a laboratory animal model is set up to measure vaccine efficacy, it is possible
to test if a change of the administration route would change the vaccine efficacy.
As a case study, we ontologically modeled two reported studies of vaccination-
challenge experiments with different vaccination routes but the same Brucella vaccine
in an established mouse model (Figure 4). RB51 is a licensed live attenuated Brucella
abortus vaccine, and the BALB/c mouse model is a well-established laboratory animal
model for Brucella vaccine research [16,24]. As shown in one study, when RB51 was
used to vaccinate a group of BALB/c mice through the intraperitoneal route (i.p.), the
vaccination induced protection in the mouse lung against i.p. challenge of the virulent
B. abortus strain S2308 [25]. However, in another study, when the intranasal route (i.n.)
was used for RB51 vaccination using the same BALB/c mouse model, the vaccinated
mice were not able to protect against i.n. challenge of virulent Brucella abortus strain
2308 in the lung [26]. The data extracted from each experiment in papers are modelled
ontologically using individuals in VO (Figure 4). Specifically, RB51 induced immune re-
sponse with/without protection against S2308 in lung is preceded by the RB51 vaccin-
ation process, which unfolds in the ‘route of administration’ (e.g., intraperitoneal route
or intranasal route). RB51 is the specific input of the RB51 vaccination and S2308 is
a participant of ‘S2308 challenge’. ‘CFU reduction assay’ has specific output ‘CFU
reduction data set’, which is about the colonization or clearance of S2308 in mouse. In
experiment 1 [25], the mouse was vaccinated through i.p. route, which led to ‘RB51-
induced immune protection against S2308 challenge’. Proceded by the i.p. vaccination,
the ‘S2308_1 challenge’ leads to the ‘reduced S2308 colonization in mouse lung_1 when
compared to control_1’ process, revealed by the ‘CFU reduction data set_1’ (is_about).
Similarly, in another experiment 2 [26], the ‘RB51-induced immune response without
protection against S2308 challenge’ was proceded by a ‘RB51 i.n. mouse vaccination_1’.
The vaccination is followed by ‘S2308_1 challenge’ and then ‘no significant change in
clearance of S2308 in mouse lung when compared to control_2’, revealed by the ‘CFU
reduction data set_2’.
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Figure 4 Modelling the RB51-induced different immune response with different route administration. The upper part of this figure models the experimental results that interperitoneal
RB51 vaccination in mice induced protection against virulent strain S2308 challenge in the lung [25]. The lower part of this figure models another study which showed that intranasal RB51
vaccination was unable to protect against virulent strain 2308 challenge in the lung as investigated in experiment 2 [26]. Filled square boxes indicate class level terms. Boxes with round corners
represent individual level data collected from papers.
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In summary, the RB51 vaccination-challenge studies clearly demonstrate that differ-
ent vaccination routes may change the outcome of the vaccine efficacy even though the
same vaccine is used. Therefore, it is critical to optimize vaccination conditions to
achieve the best vaccination results.
Combinatorial effects of vaccine formulation and administration routes to vaccine
adverse event profiles
Using the information from the package inserts of 53 licensed US vaccines listed by the
US FDA, an analysis of the effects of vaccine formulation and vaccination routes on the
advance event occurrences was conducted. In total, 53 licensed vaccines are used in
the US market. These 53 vaccines are classified into two groups: ‘live attenuated
vaccine’ and ‘nonliving vaccine’. Applying the VO’s definition of ‘live vaccine’ and ‘live
attenuated vaccine’, all the vaccines that do not contain live microbe as vaccine compo-
nent are considered nonliving vaccines, which includes inactivated vaccines, subunit
vaccines, and conjugate vaccines. Local reaction is defined as any adverse event that
occurs at the vaccination site after the vaccination. Systematic reactions are the adverse
events unfolding in the whole body or any anatomical system in human body.
Out of 53 vaccines, 13 (24.5%) are live attenuated vaccines (Table 1). The routes of
administration of these live attenuated vaccines are: subcutaneous (7, 53.8%), oral
(3, 23%), intranasal (1, 7.7%), percutaneous (2, 15.4%) and intravesical (1, 7.7%). Among
40 nonliving vaccines (Table 2), 38 (95%) are administrated intramuscularly, and 3
(7.5%) are administrated subcutaneously. The inactivated vaccine IPOL (Poliovirus Vac-
cine Inactivated manufactured by Sanofi Pasteur) is administrated either intramuscu-
larly or subcutaneously. No local reactions were reported after oral administration. The
most common local adverse events following vaccine injection are pain, induration and
tenderness at the injection site. Intranasal administration may result in nose symptoms.
Table 1 Comparison of adverse event following vaccination of 13 live attenuated human
vaccines licensed in USA
Vaccine trade name VO_ID Route of
administration
Local reactions
(Y/N)
Systematic
reactions (Y/N)
Adenovirus Type 4 and Type 7 Vaccine VO_0000096 oral N Y
Rotarix VO_0010738 oral N Y
RotaTeq VO_0000097 oral N Y
BCG Vaccine VO_0003240 percutaneous Y Y
ACAM2000 VO_0000003 percutaneous Y Y
TICE BCG VO_0000103 intravesical Y Y
FluMistW Quadrivalent VO_0000044 i.n. Y Y
Attenuvax VO_0000007 s.c. Y Y
M-M-R II VO_0000069 s.c. Y Y
ProQuad VO_0000091 s.c. Y Y
MERUVAX II VO_0000073 s.c. Y Y
Varivax VO_0000119 s.c. Y Y
YF-Vax VO_0000121 s.c. Y Y
Zostavax VO_0000124 s.c. Y Y
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Table 2 Comparison of adverse event following vaccination of 40 nonliving human
vaccines licensed in USA
Vaccine trade name VO_ID Route of
administration
Local
reactions
(Y/N)
Systematic
reactions
(Y/N)
Biothrax VO_0000014 i.m. Y Y
Diphtheria & Tetanus
Toxoids Adsorbed VO_0000033 i.m. Y Y
Tripedia VO_0000112 i.m. Y Y
Infanrix VO_0000064 i.m. Y Y
Daptacel VO_0000029 i.m. Y Y
Pediarix VO_0000082 i.m. Y Y
Kinrix VO_0000067 i.m. Y Y
Pentacel VO_0000084 i.m. Y Y
ActHIB VO_0000004 i.m. Y Y
Hiberix VO_0010715 i.m. Y Y
Liquid PedvaxHIB VO_0010723 i.m. Y Y
Comvax VO_0000028 i.m. Y Y
Havrix VO_0000052 i.m. Y Y
VAQTA VO_0010745 i.m. Y Y
TWINRIX VO_0000113 i.m. Y Y
Engerix-B VO_0010711 i.m. Y Y
RECOMBIVAX HB VO_0010737 i.m. Y Y
Gardasil VO_0000049 i.m. Y Y
CERVARIX VO_0011559 i.m. Y Y
Influenza A (H1N1) 2009 Monovalent
Vaccine (CSL Limited)
VO_0000348 i.m. Y Y
Influenza A (H1N1) 2009 Monovalent
Vaccine (ID Biomedical Corporation
of Quebec)
VO_0002499 i.m. Y Y
Influenza A (H1N1) 2009 Monovalent
Vaccine (Novartis Vaccines and
Diagnostics Limited)
VO_0000081 i.m. Y Y
Influenza A (H1N1) 2009 Monovalent
Vaccine ( Sanofi Pasteur Inc.)
VO_0000160 i.m. Y Y
Influenza Virus Vaccine, H5N1 VO_0000065 i.m. Y Y
AFLURIA VO_0000006 i.m. Y Y
Agriflu VO_0001126 i.m. Y Y
FluLaval VO_0000043 i.m. Y Y
Fluarix VO_0000045 i.m. Y Y
Fluvirin VO_0000046 i.m. Y Y
Fluzone VO_0000047 i.m. Y Y
Ixiaro VO_0011558 i.m. Y Y
JE-Vax VO_0000066 s.c. Y Y
MENVEO VO_0001246 i.m. Y Y
Menactra VO_0000071 i.m. Y Y
Menomune VO_0000072 s.c. Y Y
Pneumovax 23 VO_0000088 i.m. Y Y
Prevnar VO_0000090 i.m. Y Y
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Systematic adverse events were reported in the package inserts of all vaccines (Table 1
and Table 2).
This result indicates that formulation of vaccine and route of administration inter-
actively affect immune response. The vaccine formulation is likely a determinant factor
to decide the route of administration. Since live vaccines have the ability to invade into
the host, migrate into different areas of the body, and replicate, they can be admini-
strated using various routes such as subcutaneous, oral, and intranasal. Most of nonliv-
ing vaccines are delivered by intramuscular injection which allows the dissemination
of the antigens to the antigen presentation cells relatively easily. To promote the
antigen presentation, most nonliving vaccines need adjuvant or effective carrier compo-
nent in their formulation. Since oral administration does not relate with local reaction,
the local adverse reactions after vaccination may relate with the use of needle for
vaccine injection.
Discussion
The formulation and routes of administration of vaccines have been represented using
OWL in VO. The classification and definitions of their subclasses have been given in
this paper. The presented use cases support the hypothesis that there are combinatorial
effects of formulation and administration route on the outcomes of vaccination includ-
ing protective immune responses and vaccine adverse events. The ontological and se-
mantic modeling of vaccine formulation and administration is a starting point for
systematically analyzing various vaccine data in different resources with the goal to
identify new knowledge. It is noted that some other factors such as vaccinee’s health
condition, vaccine dose or vaccination frequency would also have an impact on the out-
come of vaccination. Those factors could be later further included to current modelling
and provide more comprehensive vaccine effect analysis.
Live attenuated vaccines can usually induce stronger protection, but they are consid-
ered unsafe in different scenarios. Killed vaccines or vaccines using part of a pathogen
organism are considered safer but usually require additives (e.g. adjuvant) to boost host
immune response to vaccine antigens. However, in the formulation of vaccines, less
additives and residuals is more benefit for vaccinees. For example, using mutant non-
toxic CRM197 (as in Menveo
W) instead of toxic diphtheria toxoid (as in MenactraW) as
conjugate protein will reduce the use of formaldehyde or other detoxifiers [27].
How risky is it to use a live attenuated vaccine in terms of vaccine safety? Our case
study shows that an orally administrated live attenuated vaccine induces systematic ad-
verse events and no local adverse events. However, the vaccine formulation is not the
only determinant for vaccine-induced immune responses. As demonstrated in our
study of the 53 licensed vaccines in the US, the live and nonliving vaccines are admini-
strated via different routes. No example can be used to compare vaccine-induced ad-
verse event or immune response if considering differences of only one variable: the
Table 2 Comparison of adverse event following vaccination of 40 nonliving human
vaccines licensed in USA (Continued)
Prevnar 13 VO_0001244 i.m. Y Y
IPOL VO_0000054 i.m. or s.c. Y Y
IMOVAX VO_0010716 i.m. Y Y
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vaccine formulation. One exception is for live vs. nonliving Japanese encephalitis vac-
cines. Both vaccines contain the same vaccine antigen and are administrated in the
same injection route. However, they are licensed and used in different countries, thus
well-controlled valuable data for systematic comparison cannot easily be obtained. To
better identify the differential immune responses by live vs. nonliving licensed Japanese
encephalitis vaccines, a systematic analysis of protective immune responses and adverse
events on a global scale is needed.
It is relatively straightforward to link local vaccine-induced adverse events (e.g., red-
ness and local pain) with the vaccine and the administration route. However, it is often
difficult to assert that systematic adverse events are induced by the administration of a
vaccine. Asserting the causal relations between systematic adverse events and vaccine
administrations is rather another topic, which is out of the scope of this paper and shall
be addressed by the Ontology of Adverse Event (OAE) [28]. Finally, a system bioinfor-
matics approach that integrates ontology modeled with analysis of gene expression
data, reported literature results, and vaccine adverse event case reports shall provide
the solution for answering the questions.
Conclusions
This is the first time that we report an OWL modeled of vaccine formulation and ad-
ministration and how they affect the vaccine-induced immune responses. Various use
cases were used to demonstrate the correlative relation between the formulation/
administration and the immune response outcome. The application of the ontological
modeled will lead to better understanding of the causal effects between immune out-
comes and different factors in vaccine preparation and vaccination.
Methods
Ontology editing
The VO development follows the OBO Foundry principles, including openness, collab-
oration, and use of a common shared syntax [29]. The format of VO ontology is W3C
standard Web Ontology Language (OWL2) (http://www.w3.org/TR/owl-guide/). For
this study, many new terms and logical definition were added into existing VO using
the Protégé 4.1 OWL ontology editor (http://protege.stanford.edu/). VO project website
is: http://www.violinet.org/vaccineontology.
Data sources for ontology development
Reference books are the main resource for classification and definition of vaccine
formulation and administration [7,30]. Definitions of terms related in this paper were
generated and reviewed by experts from the VO development team. A mail listing of
VO developers was used to discuss and achieve agreement on logical definitions. The
USA CDC pink book serves as a source for populating information related with U.S.
licensed human vaccines. The vaccine ingredients used in U.S. licensed vaccines were
manually extracted from an appendix table in the CDC pink book. The VIOLIN vaccine
database, a web-based central resource for vaccine-related research data across various
human pathogens [31], is another source for populating VO. Data used for use case
Lin and He Journal of Biomedical Semantics 2012, 3:17 Page 13 of 15
http://www.jbiomedsem.com/content/3/1/17
analyses were manually extracted from: (i) PubMed papers and (ii) package inserts of
licensed vaccines listed in US Food and Drug Administration (FDA) website [32].
Use case studies
Use case studies were designed to address the following questions: how the differences
of vaccine ingredients and/or administration routes influence vaccine efficacy or ad-
verse event reactions? To simplify the story, the effects of other factors, such as patient
health condition, vaccine dose, and vaccination frequency, are not analyzed in this
study. VO is used for classification of vaccine types in the use cases.
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